Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
The most common malignant salivary gland tumors include mucoepidermoid carcinoma and adenoid cystic carcinoma, which together account for about half of all malignant salivary gland tumors.
The pathogenesis is complex and related to radiation exposure, smoking, viral infections (such as EBV, HIV, HPV), and environmental pollution, often presenting as a local mass or pain. When the primary tumor originates from the submandibular gland or minor salivary glands, the local recurrence rate is higher. The distant metastasis rate for patients with primary parotid gland tumors is 17%, but for those with primary submandibular gland malignant tumors, it is 37%.
For patients with adenoid cystic carcinoma, special attention must be paid to distant metastasis, which can even occur 20-30 years after successful treatment of the primary tumor. Among patients who develop distant metastases, 80% occur within 8 years after treatment. Even when metastasis is known, its progression often follows an indolent course, with median survival rates at 1, 3, and 5 years being 75%, 47%, and 26.5%, respectively, without intervention.
Modern medical research continues to drive innovation in treatment methods, especially immune reconstruction cell therapy, providing new therapeutic pathways for patients.
Salivary gland tumors are relatively rare, accounting for only 6%-8% of head and neck tumors. In the United States, there are 2,000-2,500 cases annually, with parotid gland cancer accounting for about 25%. The incidence of parotid gland cancer is relatively low worldwide, but in some Asian countries such as China, Japan, and South Korea, incidence has increased. In developed countries, early screening and comprehensive treatment have improved survival rates. In parts of Southeast Asia, environmental and genetic factors have led to a gradual increase in patient numbers.
1. Strong local invasiveness
Parotid gland cancer easily invades surrounding tissues, including the facial nerve, causing facial paralysis and sensory abnormalities, severely impacting quality of life.
2. Risk of metastasis
This cancer may metastasize through the lymphatic system to cervical lymph nodes or even distant organs, increasing treatment difficulty.
3. Complexity of treatment
Due to the complexity of surrounding structures near the parotid gland, surgery carries high risks, and recurrence rates are high, posing challenges for treatment.
4. Psychological burden
Changes in facial appearance and functional impairment cause severe psychological stress and social difficulties for patients.
Immune reconstruction cell therapy activates the patient’s immune system, enhancing its ability to recognize and eliminate parotid gland cancer cells, effectively inhibiting tumor growth and metastasis.
During traditional treatments such as surgery, radiotherapy, and chemotherapy, cancer patients often face immune dysfunction, increased infection risks, and slow recovery. To better support patients, improve tolerance, and enhance quality of life, phased immune reconstruction plans tailored to different treatment cycles should be scientifically developed.
● Short-term plan: Rapidly enhance immunity through immune cell reinfusion, boosting the effectiveness of anti-tumor treatment.
● Mid-term plan: Reduce the side effects of traditional treatments, promote recovery, and complete standardized courses.
● Long-term plan: Improve immunity through immune cell reconstruction, gut immune reconstruction, elemental immune reconstruction, and immune nutrition reconstruction, thereby improving quality of life and prolonging survival.
1. Surgical treatment
Surgery is the main treatment for parotid gland cancer, aiming to completely remove tumor tissue while preserving the function of surrounding nerves and tissues. In some patients, the facial nerve may need to be preserved to reduce postoperative complications.
2. Radiotherapy and chemotherapy
Radiotherapy is often used as adjuvant treatment after surgery to reduce the risk of local recurrence. Chemotherapy is applied to advanced or metastatic patients to control tumor progression with drugs, though side effects require close management.
3. Minimally invasive treatment methods
With advances in technology, some cases of parotid gland cancer can be treated with minimally invasive techniques such as endoscopic-assisted resection or percutaneous radiofrequency ablation. These approaches reduce surgical trauma, shorten recovery time, and are suitable for early-stage or localized tumors.
Due to its strong invasiveness and treatment complexity, parotid gland cancer imposes significant physical and psychological burdens on patients, requiring active diagnosis and comprehensive treatment. Experts at United Life International Medical Center emphasize that combining immune reconstruction cell therapy with traditional methods represents an important future direction for parotid gland cancer treatment, significantly improving cure rates and quality of life.
